Home » Newsletters » BioWorld Science

BioWorld Science

June 20, 2001

View Archived Issues

Chronic therapy with ximelagatran for preventing stroke in patients with atrial fibrillation

Clinical hold placed on GM-611 pending analysis of animal toxicity studies

Licensing agreement signed for Chugai psoriasis therapeutic

Adipocyte-specific protein and essential hypertension

Phase I trials commence with Ilex Oncology's ILX-651 and NM-3

Progen receives U.S. approval to begin phase II trial of PI-88

MTX-HSA is superior to free MTX in a mouse model of rheumatoid arthritis

Risedronate approved in additional E.U. countries for reducing hip fractures

Synthetic halichondrin B analogues show high antitumor potency and wide therapeutic window

FDA issues nonapprovable letter for Zelnorm as IBS treatment

BLS successfully develops GMP manufacturing process for troponin I

Nonpeptide FSH mimetics useful for the treatment of infertility

New GLA-60 analogues designed at Sankyo inhibit macrophage activity

Roche and Trimeris expand partnership agreement for HIV fusion inhibitors

Inhibitors of tyrosine kinase from Merck useful as antiangiogenic agents

Reminyl shows potential for treatment of cerebrovascular disease-related dementia

Positive modulators of nicotinic receptor agonists in the AstraZeneca pipeline

Cannabinoid CB1 antagonists and their use reported by French lab

Plant extracts with significant efficacy in animal model of NIDDM

CollaGenex seeks pan-European approval for Periostat tablets

European launch of Zometa for TIH under way

Phase I/II study of ISIS-14803 shows dose-dependent viral load reductions

Role of calcineurin in cardiac hypertrophy and subsequent heart failure

Repligen extends phase II autism trial; biological markers/response to secretin relation reported

Two drugs will be reviewed by Endocrinologic and Metabolic Drugs Advisory Committee next month

Medarex and Genmab to codevelop antibody therapeutics for inflammation

Sanofi-Synthelabo designs selective CB2 antagonists

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...